The minimum element of a synthetic peptide required to block prostate tumor cell migration

Human prostate tumor cell invasion and metastasis is dependent in part on cell adhesion to extracellular matrix proteins and cell migration. We previously identified a synthetic D-amino acid tumor cell adhesion peptide called HYD1 (kikmviswkg) that supported adhesion of tumor cells derived from breast, prostate, ovary and pancreas tissue. Alanine substitution analysis and a peptide deletion strategy were used to determine the minimal element of HYD1 necessary for bioactivity in a prostate cancer cell line called PC3N. Bioactivity was measured by assays of cell adhesion, migration and ERK signaling. The most potent element of HYD1 necessary to support cell adhesion was kmvixw, the block to migration required xkmviswxx and activation of ERK signaling required ikmviswxx. The shortest sequence active in all three assays was iswkg. The HYD1 peptide contains overlapping elements required for adhesion, blocking migration and the activation of ERK signaling. These linear peptide sequences provide the starting point for development of novel compounds to target cancer cell adhesion and migration.

[1]  A. Cress,et al.  Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5. , 2006, Carcinogenesis.

[2]  T. Kawaguchi Cancer metastasis: characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. , 2005, Current drug targets. Cardiovascular & haematological disorders.

[3]  K. Lam,et al.  The use of a combinatorial library method to isolate human tumor cell adhesion peptides , 1996, Molecular Diversity.

[4]  Jer-Tsong Hsieh,et al.  The role of cell adhesion molecule in cancer progression and its application in cancer therapy. , 2004, Acta biochimica Polonica.

[5]  S. Hibino,et al.  Identification of an Active Site on the Laminin α5 Chain Globular Domain That Binds to CD44 and Inhibits Malignancy , 2004, Cancer Research.

[6]  H. Jin,et al.  Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.

[7]  H. Oettle,et al.  Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. , 2004, Oral oncology.

[8]  K. Lam,et al.  Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. , 2004, Bioorganic & medicinal chemistry letters.

[9]  S. Hibino,et al.  Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. , 2003, Cancer research.

[10]  H. Kleinman,et al.  The basement membrane matrix in malignancy , 2003, The Journal of pathology.

[11]  G. Tucker Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.

[12]  K. Lam,et al.  Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. , 2003, Accounts of chemical research.

[13]  Lee M Ellis,et al.  Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. , 2003, Cancer research.

[14]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. , 2003, European journal of cancer.

[15]  Jeffrey W. Smith Cilengitide Merck. , 2003, Current opinion in investigational drugs.

[16]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[17]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[18]  Lee Makowski,et al.  One from column A and two from column B: the benefits of phage display in molecular-recognition studies. , 2002, Current opinion in chemical biology.

[19]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[20]  Kit S Lam,et al.  Therapeutic cancer targeting peptides. , 2002, Biopolymers.

[21]  S. Mousa,et al.  The alpha v integrin antagonists as novel anticancer agents: an update. , 2002, Expert opinion on investigational drugs.

[22]  K. Lamborn,et al.  Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. , 2002, Cancer research.

[23]  R. Benjamin,et al.  Pilot study of vitaxin—an angiogenesis inhibitor—in patients with advanced leiomyosarcomas , 2001, Cancer.

[24]  K. Lam,et al.  Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. , 2001, Cancer research.

[25]  J. Posey,et al.  A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[26]  P. Grieco,et al.  Preparation of 'side-chain-to-side-chain' cyclic peptides by Allyl and Alloc strategy: potential for library synthesis. , 2001, The journal of peptide research : official journal of the American Peptide Society.

[27]  K. Mikecz Vitaxin applied molecular evolution. , 2000, Current opinion in investigational drugs.

[28]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  I. Macdonald,et al.  Clinical targets for anti-metastasis therapy. , 2000, Advances in cancer research.

[30]  R. Nagle,et al.  N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. , 1999, The American journal of pathology.

[31]  N. Fusenig,et al.  Epidermal differentiation and basement membrane formation by HaCaT cells in surface transplants. , 1998, European journal of cell biology.

[32]  M. Nomizu,et al.  Activation of β1 Integrin Signaling Stimulates Tyrosine Phosphorylation of p190 RhoGAP and Membrane-protrusive Activities at Invadopodia* , 1998, The Journal of Biological Chemistry.

[33]  H. Kleinman,et al.  Liver metastasis formation by laminin‐1 peptide (LQVQLSIR)‐adhesion selected B16‐F10 melanoma cells , 1997, International journal of cancer.

[34]  Kit S. Lam,et al.  The "One-Bead-One-Compound" Combinatorial Library Method. , 1997, Chemical reviews.

[35]  I. Rabinovitz,et al.  The integrin alpha 6 beta 4 and the biology of carcinoma. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[36]  A. Utani,et al.  Identification of Cell Binding Sites in the Laminin α1 Chain Carboxyl-terminal Globular Domain by Systematic Screening of Synthetic Peptides (*) , 1995, The Journal of Biological Chemistry.

[37]  K. Friedrichs,et al.  High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. , 1995, Cancer research.

[38]  R. Nagle,et al.  The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. , 1995, Cancer metastasis reviews.

[39]  H. Kleinman,et al.  The laminin alpha 1 chain Ile-Lys-Val-Ala-Val (IKVAV)-containing peptide promotes liver colonization by human colon cancer cells. , 1995, Cancer research.

[40]  M. Rothmund,et al.  Expression and Distribution of VLA Receptors in the Pancreas: An Immunohistochemical Study , 1993, Pancreas.

[41]  M. Rothmund,et al.  Expression and function of VLA-alpha 2, -alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma. , 1992, International journal of cancer.

[42]  T. Carey,et al.  Culture conditions affect expression of the alpha 6 beta 4 integrin associated with aggressive behavior in head and neck cancer. , 1992, Advances in experimental medicine and biology.

[43]  Kit S. Lam,et al.  A new type of synthetic peptide library for identifying ligand-binding activity , 1992, Nature.

[44]  A. Skubitz,et al.  Synthetic peptides from the carboxy-terminal globular domain of the A chain of laminin: their ability to promote cell adhesion and neurite outgrowth, and interact with heparin and the beta 1 integrin subunit , 1991, The Journal of cell biology.

[45]  R. Barrett,et al.  Peptides on phage: a vast library of peptides for identifying ligands. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Devlin,et al.  Random peptide libraries: a source of specific protein binding molecules. , 1990, Science.

[47]  E. Ruoslahti,et al.  Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides [published erratum appears in J Cell Biol 1989 Jun;108(6):following 2546] , 1988, The Journal of cell biology.

[48]  H. Kleinman,et al.  YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. , 1987, Science.

[49]  E Ruoslahti,et al.  New perspectives in cell adhesion: RGD and integrins. , 1987, Science.

[50]  M. Humphries,et al.  A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. , 1986, Science.

[51]  Erkki Ruoslahti,et al.  Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.

[52]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.